AI tech could help prevent onset of diabetes

The Mealplanner Europe, a Finnish medtech company creating software that plans and organises nutrition for users, and MediSapiens, a developer and provider of genomic, biomedical and health data solutions, have partnered to develop an application for helping users in the prevention of onset of type 2 diabetes.

The development is funded by an EU grant from the Permides (Personalised Medicine Innovation through Digital Enterprise Solutions) project.

The joint project aims at developing a novel application which helps users to assess the risk of developing type 2 diabetes and plan their nutrition in order to prevent the onset of diabetes.

The application will be built to utilise novel AI-based methods for risk assessment. The projected launch of the application is during the second quarter of 2018.

“We’re thrilled to engage in this development with a solid, science-backed company working in the emerging field of personalised nutrition. This highlights our commitment to work for better future health through better and more efficient use of data.

“Type 2 diabetes is a global threat with rising incidence, and the potential healthcare cost savings of prevention of Type 2 diabetes are substantial” said Marko Kuisma, CCO of MediSapiens.

Type 2 diabetes has reached epidemic levels in the world population, including an alarming proportion of children.

Indicative is that globally, nearly 28% of women aged 30-45 are diabetic.

The focus of primary healthcare concentrates on treating the symptoms of the disease rather than prevention even though Type 2 diabetes can be reversed through proper diet, exercise and medication.

The technology being developed by The Mealplanner and MediSapiens is designed to prevent Type 2 diabetes rather than treat it after it has occurred.

Dave is the Editor of Med-Tech Innovation magazine. He also holds the position of Deputy Group Editor for the Rapid Life Sciences portfolio. You can reach Dave via his email -

'AI tech could help prevent onset of diabetes' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Privacy policy

Terms and conditions